Leyden Labs has secured €20 million in financing from the European Investment Bank (EIB), supported by HERA Invest under the EU’s InvestEU programme.
The funding will support the clinical development of Leyden Labs’ PanFlu nasal spray, an intranasal antibody therapy designed to protect against a broad range of influenza viruses, including seasonal flu, avian flu (H5), and future respiratory threats. Unlike traditional vaccines, this approach offers direct, fast-acting protection at the site of infection: the respiratory mucosa.
With this investment, Leyden Labs takes a major step forward in preparing for future pandemics through scalable, accessible prevention strategies that complement existing vaccine efforts.
Read more here
